CagriSema vs Ozempic: Dual Amylin/GLP-1 Synergy vs Single GLP-1 Agonism
When comparing CagriSema and Ozempic, the crucial evolutionary advance is dual-receptor targeting. Ozempic relies exclusively on Semaglutide to activate GLP-1 receptors, regulating blood sugar and slowing digestion. CagriSema retains the full power of Semaglutide while adding Cagrilintide, an analog of the pancreatic hormone amylin that coordinates stomach emptying and triggers satiety signals in the hindbrain. This delivers unprecedented appetite control with superior fat mass reduction.
Feature-by-Feature Comparison
CagriSema
Ozempic
| Feature / Capability | CagriSema | Ozempic |
|---|---|---|
| Active Compound | Cagrilintide + Semaglutide | Semaglutide only |
| Mechanism | Dual amylin & GLP-1 co-agonist | Selective GLP-1 agonist |
| Administration | Once-weekly subcutaneous pen | Once-weekly subcutaneous pen |
| Average Weight Reduction | Up to 24-25% | Up to 15-17% |
| Food Noise Suppression | Complete (Hypothalamus + Area Postrema) | Strong (Hypothalamus) |
| Generic Available | ||
| Starting Price | $280.00 – $680.00 | $180.00 – $420.00 |
| View CagriSema | View Ozempic |
The Final Verdict
CagriSema is significantly more potent than Ozempic because it combines Cagrilintide (an amylin receptor agonist) with Semaglutide. This dual mechanism delivers up to 25% average weight reduction, making it ideal for patients who plateaued on Ozempic.
Medical Disclaimer
This comparison is for informational purposes only and does not constitute medical advice. The accuracy of pricing and features may change over time. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication.
Last updated: September 2026